Can-Fite Biopharma shares surge 18.15% after-hours as company announces strategic partnerships for Namodenoson at BioFIT 2025.

Can-Fite BioPharma surged 18.15% in after-hours trading following the announcement of its participation in BioFIT 2025, where the company aims to advance a veterinary partnership for its Phase III anti-cancer drug, Namodenoson. The news highlighted Namodenoson’s potential in the veterinary oncology market, projected to reach $3.1 billion by 2030, and referenced a prior partnership with Vetbiolix that could generate $325 million in royalties. This strategic move underscores the company’s focus on expanding Namodenoson’s applications and securing collaborations with major animal health firms like Elanco and Zoetis. Despite underlying financial challenges, the bullish reaction reflects optimism around new partnership opportunities and the drug’s strong clinical profile, including its demonstrated safety and anti-tumor efficacy.